Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy

This study shows that ESL was well tolerated and efficacious as add-on therapy to one baseline AED. The use of ESL in patients less refractory than those included in previous clinical trials led to higher responder and seizure freedom rates. No new safety issues were observed.